Drug intelligence / Profile preview

potravitug

Development stage: Phase 3
Lead developer: Memo Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Potravitug is a fully human monoclonal antibody developed by Memo Therapeutics AG for the treatment and prevention of BK virus (BKV) infection and BK virus nephropathy (BKVN) in kidney transplant recipients. Discovered using the proprietary DROPZYLLA® platform, the antibody targets the VP1 capsid protein of the BK polyomavirus. By binding to VP1, potravitug blocks the virus from attaching to and entering target cells, thereby neutralizing the infection and preventing graft dysfunction or loss. It has received FDA Fast Track designation and has demonstrated clinical activity in reducing viral loads in Phase II trials, with Phase III development planned for 2026.

Other names: potravitug

Targets

Norovirus VP1

Beyond the preview

Go deeper on potravitug.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on potravitug.

Explore the full profile